ARTL

Artelo Biosciences (ARTL)

About Artelo Biosciences (ARTL)

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

Details

Daily high

$1.12

Daily low

$1.10

Price at open

$1.11

52 Week High

$1.78

52 Week Low

$1.00

Market cap

3.6M

Dividend yield

0.00%

Volume

1,696

Avg. volume

6,316

P/E ratio

-.34

Artelo Biosciences News